Use of vitamin K antagonist therapy in geriatrics: A french national survey from the french society of geriatrics and gerontology (SFGG)

Drugs and Aging

Volumn 30, Issue 12, 2013, Pages 1019-1028

  Plichart, Matthieu ^a,b,c,d   Berrut, Gilles ^a,e   Maubourguet, Nathalie ^a   Jeandel, Claude ^a   Emeriau, Jean Paul ^a   Ankri, Joël ^a   Bouvier, Hélène ^a   Ruault, Geneviève ^a   Hanon, Olivier ^a,b,c  

^a French Society of Geriatrics and Gerontology   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIBIOTIC AGENT; ANTIVITAMIN K; FLUINDIONE; PARACETAMOL; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

AGED; ARTICLE; BLEEDING; COMORBIDITY; CROSS-SECTIONAL STUDY; DEMENTIA; DEPRESSION; DRUG USE; FALLING; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL SOCIETY; NURSING HOME; PRESCRIPTION; PRIORITY JOURNAL; REHABILITATION CARE; TREATMENT INDICATION; VERY ELDERLY;

AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION REVIEW; FEMALE; FRANCE; GERIATRICS; HUMANS; LOGISTIC MODELS; MALE; QUESTIONNAIRES; SOCIETIES, MEDICAL; VITAMIN K;

EID: 84892914026     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0127-3     Document Type: Article

References (54)

1. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S-75S.
2. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e576S-600S.
3. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-494S.
4. Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, et al. Venous thromboembolism in the elderly. A communitybased perspective. Thromb Haemost. 2008;100(5):780-8.
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370-5.
6. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689-96.
7. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348(9025):423-8.
8. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999-1002.
9. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124(7):824-9.
10. Bauersachs RM. Use of anticoagulants in elderly patients. Thromb Res. 2012;129(2):107-15.
11. Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther. 2008;6(1):57-70.
12. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-9.
13. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029-37.
14. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968-77.
15. Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis. 2013;35(3):333-5.
16. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-47.
17. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: The international study of anticoagulation management (ISAM). J Thromb Thrombolysis. 2007;23(2):83-91.
18. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manage Care Pharm. 2009;15(3):244-52.
19. Melamed OC, Horowitz G, Elhayany A, Vinker S. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manage Care. 2011;17(3):232-7.
20. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost. 2008;6(10):1647-54.
21. Karki S, Lander S. Evaluation of anticoagulation therapy in an academic nursing home. J Pharm Technol. 2003;19:141-5.
22. Aspinall SL, Zhao X, Handler SM, Stone RA, Kosmoski JC, Libby EA, et al. The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. J Am Geriatr Soc. 2010;58(8):1475-80.
23. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157(9):978-84.
24. Gurwitz JH, Field TS, Radford MJ, Harrold LR, Becker R, Reed G, et al. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007;120(6):539-44.
25. Lackner TE, Battis GN. Use of warfarin for nonvalvular atrial fibrillation in nursing home patients. Arch Fam Med. 1995;4(12):1017-26.
26. McCormick D, Gurwitz JH, Goldberg RJ, Becker R, Tate JP, Elwell A, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161(20):2458-63.
27. Verhovsek M, Motlagh B, Crowther MA, Kennedy C, Dolovich L, Campbell G, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review. BMC Geriatr. 2008;8:13.
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
29. French National Agency on Drugs and Safety - Agence Nationale de la Sécurité des Médicaments (online). Mise au point sur le bon usage des médicaments antivitamine K (AVK); 2009. http://ansm.sante.fr/ var/ansm-site/storage/original/application/5e41e9188c8a23330bc0f0461821d691.pdf. Accessed 16 Sep 2013.
30. Neidecker M, Patel AA, Nelson WW, Reardon G. Use of warfarin in long-term care: A systematic review. BMC Geriatr. 2012;12:14.
31. Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, et al. Risks factors for highly unstable response to oral anticoagulation: A case-control study. Br J Haematol. 2005;129(1):72-8.
32. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):445-885.
33. Lacut K, Ayme-Dietrich E, Gourhant L, Poulhazan E, Andro M, Becquemont L, et al. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. Br J Clin Pharmacol. 2012;73(3):428-36.
34. Comets E, Diquet B, Legrain S, Huisse MG, Godon A, Bruhat C, et al. Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. Clin Pharmacol Ther. 2012;91(5):777-86.
35. Verstuyft C, Delavenne X, Rousseau A, Robert A, Tod M, Diquet B, et al. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clin Pharmacokinet. 2012;51(1):41-53.
36. Pautas E, Peyron I, Bouhadiba S, Golmard JL, Gouronnec A, Oboa N, et al. Reversal of overanticoagulation in very elderly hospitalized patients with an INR above 5.0: 24-hour INRresponse after vitamin K administration. Am J Med. 2011;124(6):527-33.
37. Mentre F, Pousset F, Comets E, Plaud B, Diquet B, Montalescot G, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther. 1998;63(1):64-78.
38. Fihn SD, Gadisseur AA, Pasterkamp E, van der Meer FJ, Breukink- Engbers WG, Geven-Boere LM, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost. 2003;90(2):260-6.
39. Mahe I, Grenard AS, Joyeux N, Caulin C, Bergmann JF. Management of oral anticoagulant in clinical practice: A retrospective study of 187 patients. J Gerontol A Biol Sci Med Sci. 2004;59(12):1339-42.
40. Pautas E, Despres J, Peyron I, Golmard JL, Grange J, Koenig N, et al. Divisibility of warfarin and fluindione tablets tested in elderly patients and their family circle [in French]. Geriatr Psychol Neuropsychiatr Vieil. 2011;9(2):171-7.
41. Pautas E, Gouin-Thibault I, Debray M, Gaussem P, Siguret V. Haemorrhagic complications of vitamin K antagonists in the elderly: risk factors and management. Drugs Aging. 2006;23(1): 13-25.
42. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost. 2001;86(2): 569-74.
43. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: A systematic review. Age Ageing. 2011;40(6):675-83.
44. Bond AJ, Molnar FJ, Li M, Mackey M, Man-Son-Hing M. The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy. Thromb J. 2005;3(1):1.
45. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl): 2575-2985.
46. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612-7.
47. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54(8):1231-6.
48. Sconce EA, Kamali F. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: The need for a more tailored dosing regimen. Eur J Haematol. 2006;77(6):457-62.
49. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol. 2003;120(3):526-8.
50. Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med. 2005;165(13):1527-32.
51. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009;114(5):952-6.
52. French National Agency on Drugs Safety - Agence Nationale de la Sécurité des Médicaments. Les anticoagulants en France en 2012: etat des lieux et surveillance; 2012. http://ansm.sante.fr/var/ansm-site/ storage/original/application/901e9c291a545dff52c0b41365c0d6e2.pdf Accessed 16 Sep 2013.
53. Siguret V, Gouin-Thibault I, Gaussem P, Pautas E. Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly. Drugs Aging. 2013;30(9):687-99.
54. Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahe I, et al. Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen. Am J Med. 2005;118(2): 137-42.